Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 67,608 Shares

Verona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli sold 67,608 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $5.00, for a total transaction of $338,040.00. Following the completion of the sale, the chief executive officer now owns 15,007,816 shares of the company’s stock, valued at approximately $75,039,080. This represents a 0.45 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

David Zaccardelli also recently made the following trade(s):

• On Friday, December 6th, David Zaccardelli sold 162,800 shares of Verona Pharma stock. The stock was sold at an average price of $5.01, for a total transaction of $815,628.00.
• On Monday, December 2nd, David Zaccardelli sold 3,200 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total transaction of $16,000.00.
• On Friday, November 29th, David Zaccardelli sold 98,888 shares of Verona Pharma stock. The stock was sold at an average price of $5.01, for a total transaction of $495,428.88.
• On Wednesday, November 27th, David Zaccardelli sold 23,240 shares of Verona Pharma stock. The shares were sold at an average price of $5.00, for a total transaction of $116,200.00.
• On Monday, November 11th, David Zaccardelli sold 2,400 shares of Verona Pharma stock. The stock was sold at an average price of $5.00, for a total transaction of $12,000.00.
• On Monday, November 4th, David Zaccardelli sold 94,144 shares of Verona Pharma stock. The stock was sold at an average price of $4.39, for a total transaction of $413,292.16.
• On Friday, November 1st, David Zaccardelli sold 46,888 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $205,369.44.
• On Friday, October 25th, David Zaccardelli sold 4,800 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $21,024.00.
• On Wednesday, October 23rd, David Zaccardelli sold 16 shares of Verona Pharma stock. The stock was sold at an average price of $4.38, for a total transaction of $70.08.
• On Monday, October 21st, David Zaccardelli sold 110,456 shares of Verona Pharma stock. The shares were sold at an average price of $4.38, for a total transaction of $483,797.28.

Verona Pharma Stock Performance

VRNA opened at $40.50 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 12.88 and a current ratio of 13.03. The company’s 50-day simple moving average is $35.74 and its two-hundred day simple moving average is $26.18. Verona Pharma plc has a 52-week low of $11.39 and a 52-week high of $40.76.

Verona Pharma (NASDAQ:VRNA) last posted its earnings results on Monday, November 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.12). The business had revenue of $5.62 million for the quarter, compared to analyst estimates of $2.31 million. During the same quarter in the prior year, the company earned ($0.18) EPS. On average, research analysts forecast that Verona Pharma plc will post -2.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on VRNA. Wells Fargo & Company upped their target price on shares of Verona Pharma from $50.00 to $64.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. HC Wainwright upped their target price on shares of Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Truist Financial upped their price target on shares of Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Finally, Canaccord Genuity Group upped their price target on shares of Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $43.83.

Hedge Funds Weigh In On Verona Pharma

Several institutional investors have recently made changes to their positions in the business. NEA Management Company LLC lifted its stake in shares of Verona Pharma by 9.3% in the 2nd quarter. NEA Management Company LLC now owns 5,584,753 shares of the company’s stock worth $80,756,000 after purchasing an additional 476,190 shares during the period. Maverick Capital Ltd. lifted its stake in shares of Verona Pharma by 36.3% in the 3rd quarter. Maverick Capital Ltd. now owns 4,215,973 shares of the company’s stock worth $121,294,000 after purchasing an additional 1,123,166 shares during the period. Frazier Life Sciences Management L.P. lifted its stake in shares of Verona Pharma by 2.1% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 3,383,950 shares of the company’s stock worth $97,356,000 after purchasing an additional 69,601 shares during the period. Eventide Asset Management LLC increased its holdings in Verona Pharma by 359.6% in the 3rd quarter. Eventide Asset Management LLC now owns 2,425,846 shares of the company’s stock worth $69,792,000 after acquiring an additional 1,898,065 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in Verona Pharma by 19.6% in the 3rd quarter. Wellington Management Group LLP now owns 1,878,632 shares of the company’s stock worth $54,048,000 after acquiring an additional 307,272 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.